Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2

  1. Takahiro Kageyama
  2. Shigeru Tanaka
  3. Keishi Etori
  4. Koto Hattori
  5. Kazusa Miyachi
  6. Tadamichi Kasuya
  7. Taro Iwamoto
  8. Kei Ikeda
  9. Hidetoshi Igari
  10. Koutaro Yokote
  11. Hiroshi Nakajima

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.vaccine.2022.02.045
  2. ScreenIT

    SciScore for 10.1101/2021.06.21.449182: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsField Sample Permit: The study procedures for sample collection and those for analyses were approved by Chiba University Ethics Committee on February 24th, 2021 (No. HS202101-03) and April 21st, 2021 (No. HS202104-01), respectively.
    IRB: The study procedures for sample collection and those for analyses were approved by Chiba University Ethics Committee on February 24th, 2021 (No. HS202101-03) and April 21st, 2021 (No. HS202104-01), respectively.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Among them, we selected 20 high responders and 20 low responders against the BNT162b2 mRNA vaccine based on anti-SARS-CoV-2S antibody titer.
    anti-SARS-CoV-2S
    suggested: None
    For the analysis of T cells, cells were stained with antibodies against CCR7 (150503, BD), CD4 (RPA-T4, Biolegend), CD45RA (HI100, BD), CD38 (HIT2, BD), CD8 (SK1, BD), CD3 (UCHT1, BD), and HLA-DR (G46-6, BD).
    CCR7
    suggested: None
    CD4
    suggested: None
    CD45RA
    suggested: None
    CD38
    suggested: None
    CD8
    suggested: None
    CD3
    suggested: None
    HLA-DR
    suggested: None
    For the analysis of B cells, cells were stained with antibodies against CD24 (ML5, BD), CD19 (SJ25C1, BD), CD27 (O323, Biolegend), CD38, CD20 (2H7, BD), and IgD (IA6-2, BD).
    CD24
    suggested: None
    CD19
    suggested: (Agilent Cat# TC67401, RRID:AB_579635)
    CD27
    suggested: None
    CD20
    suggested: None
    For the analysis of monocytes, cells were stained with antibodies against CD16 (B73.1, BD), CD14 (MfP9, BD), and HLA-DR.
    CD16
    suggested: (BioLegend Cat# 348805, RRID:AB_2889063)
    CD14
    suggested: None
    Software and Algorithms
    SentencesResources
    Data were collected by a Canto II (BD) and analyzed by FlowJo software (BD).
    FlowJo
    suggested: (FlowJo, RRID:SCR_008520)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.06.21.449182v1 on bioRxiv